Overview
Hereditary transthyretin-mediated amyloidosis (hATTR) is often under-recognized and misdiagnosed, which can lead to delayed treatment and poor patient outcomes, such as irreversible disease progression, loss of quality of life, and even death.1-7 That’s why identifying patients in a timely manner is critical: the sooner a patient with hereditary ATTR is diagnosed, the earlier clinicians can help preserve their function, independence, and quality of life.1,3 Joining Dr Jennifer Caudle to discuss the key challenges associated with diagnosing hereditary ATTR and clinical perspectives on addressing them in both cardiology and neurology settings are Drs Kevin Alexander and Anasheh Halabi. Dr Alexander is an advanced heart failure-trained cardiologist and an Assistant Professor of Cardiovascular Medicine at Stanford University School of Medicine in Palo Alto, California. Dr Halabi is an Assistant Clinical Professor in the Department of Neuromuscular Neurology and Director of the Neuropathy Program at the David Geffen School of Medicine at UCLA.